The Science Behind the Berberine Patch

Berberine is one of the best-studied plant alkaloids in metabolic medicine. The clinical evidence comes from the ORAL route at roughly 500 mg per dose, usually three times daily (about 1,000-1,500 mg/day).

Liu et al. (Frontiers in Pharmacology 2025;16:1572197; PROSPERO CRD42024588614) pooled randomised placebo-controlled trials of berberine on the components of metabolic syndrome. Berberine significantly reduced triglycerides (WMD -0.367 mmol/L; 95% CI -0.560 to -0.175; p < 0.001), fasting plasma glucose (WMD -0.515 mmol/L; 95% CI -0.847 to -0.183; p = 0.002) and waist circumference (WMD -3.270 cm; 95% CI -4.818 to -1.722; p < 0.001). Secondary endpoints improved as well: LDL cholesterol (-0.495 mmol/L; 95% CI -0.714 to -0.276; p < 0.001), total cholesterol (-0.451 mmol/L; p < 0.001), BMI (-0.435 kg/m2; 95% CI -0.856 to -0.013; p = 0.043) and two-hour oral glucose tolerance (-1.606 mmol/L; 95% CI -1.891 to -1.321; p < 0.001).

Xie et al. (Frontiers in Pharmacology 2022;13:1015045) pooled 37 randomised trials in 3,048 patients with type 2 diabetes: fasting plasma glucose -0.82 mmol/L (95% CI -0.95 to -0.70), HbA1c -0.63% (95% CI -0.72 to -0.53), two-hour postprandial glucose -1.16 mmol/L (95% CI -1.36 to -0.96). Berberine did not increase total adverse events (RR 0.73; 95% CI 0.55 to 0.97).

Zhao et al. (Journal of Nutrition 2023;153(10):2939-2950; 20 trials, n = 1,761) found fasting glucose -0.52 mmol/L (95% CI -0.72 to -0.33; 18 studies, n = 1,522), HbA1c -4.48 mmol/mol (95% CI -6.53 to -2.44; 7 studies, n = 756), fasting insulin -2.36 mU/L (95% CI -3.64 to -1.08), HOMA-IR -0.85 (95% CI -1.16 to -0.53; 12 studies, n = 1,065) and two-hour postprandial glucose -1.81 mmol/L (95% CI -2.37 to -1.24).

An umbrella meta-analysis of existing meta-analyses (Nazari et al., Clinical Therapeutics 2024;46(2):e64-e72) confirms the direction: fasting blood glucose ES-WMD -0.77 (95% CI -0.90 to -0.63), HbA1c -0.57 (95% CI -0.68 to -0.46), HOMA-IR -1.04 (95% CI -1.66 to -0.42), plus reductions in interleukin-6, TNF-alpha and C-reactive protein.

Across four independent syntheses the direction and the magnitude of effect are consistent: oral berberine lowers fasting glucose, HbA1c, postprandial glucose, insulin resistance and atherogenic lipids against placebo. Berberine is a metabolically active molecule in humans, and the case for delivering it by a route that avoids the gut is set out under transdermal delivery above.

Chromium is an essential trace element and one of the very few substances in this formula that carries an authorised health claim in the European Union.

The EFSA Panel on Dietetic Products, Nutrition and Allergies assessed chromium claims under Article 13(1) of Regulation (EC) No 1924/2006 and published its scientific opinion in the EFSA Journal (2010;8(10):1732). Two claims were positively assessed and subsequently authorised by Commission Regulation (EU) No 432/2012 of 16 May 2012: chromium contributes to normal macronutrient metabolism, and chromium contributes to the maintenance of normal blood glucose levels. Both may be used only for foods that are at least a source of trivalent chromium.

On appetite specifically, Anton et al. (Diabetes Technology and Therapeutics 2008;10(5):405-412) ran a double-blind, placebo-controlled trial in 42 overweight adult women who reported carbohydrate cravings, randomised to 1,000 micrograms per day of chromium picolinate or placebo for 8 weeks. Food intake at breakfast, lunch and dinner was directly measured - not self-reported - at baseline, week 1 and week 8. Compared with placebo, chromium picolinate reduced food intake (p < 0.0001), hunger ratings (p < 0.05) and fat cravings (p < 0.0001). In a companion ANIMAL STUDY in Sprague-Dawley rats, chromium picolinate injected directly into the third ventricle reduced spontaneous 24-hour food intake dose-dependently (p < 0.05). The authors conclude the appetite signal is likely mediated by a direct central effect.

Route studied: the EFSA assessment and the appetite trial both concern ORAL intake, the trial at 1,000 micrograms per day.

Green tea extract is standardised to catechins, of which epigallocatechin-3-gallate (EGCG) is the most abundant and the most studied. Every human result below was produced with ORAL capsules.

The largest synthesis is a systematic review and dose-response meta-analysis of 59 randomised controlled trials in 3,802 participants (Asbaghi et al., British Journal of Nutrition 2024;131(7):1125-1157). Pooled across trials, oral green tea extract significantly reduced body mass, body-fat percentage and BMI, and significantly reduced malondialdehyde while increasing total antioxidant capacity and adiponectin.

At the level of a single trial, Chen et al. (Clinical Nutrition 2016;35(3):592-599; ClinicalTrials.gov NCT02147041) randomised 102 women with central obesity (BMI at or above 27 kg/m2, waist circumference at or above 80 cm) to 856.8 mg EGCG per day or placebo for 12 weeks, double-blind. Body weight fell from 76.8 +/- 11.3 kg to 75.7 +/- 11.5 kg (p = 0.025), with significant reductions in BMI (p = 0.018) and waist circumference (p = 0.023). Ghrelin was significantly lower and adiponectin significantly higher than placebo. No adverse events were recorded.

A more recent double-blind RCT (Wilasrusmee et al., Scientific Reports 2024;14:21628) gave 150 mg EGCG twice daily for 8 weeks to subjects with obesity (n = 30, no dietary restriction). Systolic and diastolic blood pressure and mean arterial pressure fell significantly (p < 0.05), alongside a shift in heart-rate variability toward sympathetic dominance.

Across 59 trials and more than 3,800 participants the catechin class has a replicated metabolic signal in humans, measured against placebo. Route and dose studied: oral capsules, 300 to about 860 mg EGCG per day.

5-hydroxytryptophan is the direct metabolic precursor of serotonin and, unlike serotonin itself, crosses the blood-brain barrier. The satiety evidence consists of three double-blind, placebo-controlled human trials, all using the ORAL route.

Ceci et al. (Journal of Neural Transmission 1989;76(2):109-117) enrolled 19 obese women with BMI between 30 and 40 in a double-blind crossover study. Either 5-HTP at 8 mg/kg/day or placebo was given for five weeks with no dietary restriction. Food intake was recorded with a three-day diet diary. 5-HTP promoted typical anorexia-related symptoms, decreased food intake and weight loss.

Cangiano et al. (American Journal of Clinical Nutrition 1992;56(5):863-867) randomised 20 obese patients to 5-HTP 900 mg/day or placebo, double-blind, across two consecutive 6-week periods: no diet prescribed in the first period, a 5,040 kJ/day (about 1,200 kcal) diet recommended in the second. Significant weight loss occurred in the 5-HTP group in both periods, together with a reduction in carbohydrate intake and a consistent presence of early satiety. Tolerance was good.

Cangiano et al. (International Journal of Obesity 1998;22(7):648-654) randomised 25 overweight patients with non-insulin-dependent diabetes to 5-HTP 750 mg/day or placebo for two weeks, double-blind, with no dietary restriction; 20 completed. Brain tryptophan availability was significantly lower in the diabetic patients than in healthy controls at baseline. Patients receiving 5-HTP significantly decreased daily energy intake by reducing both carbohydrate and fat intake, and lost weight.

The mechanism - serotonergic modulation of appetite and macronutrient selection - is well established in pharmacology, and the three trials point consistently the same way: earlier satiety, lower energy intake, reduced carbohydrate selection. Route and dose studied: oral capsules, 750-900 mg/day or 8 mg/kg/day.

Safety point specific to this ingredient: 5-HTP acts on the serotonin system and must not be combined with SSRIs, SNRIs, MAO inhibitors, tricyclics, triptans, tramadol, lithium or St John's wort without medical supervision, because of the risk of serotonin syndrome.

L-theanine is a non-protein amino acid found almost exclusively in tea (Camellia sinensis). The evidence base consists of randomised, placebo-controlled human trials, all using the ORAL route.

Hidese et al. (Nutrients 2019;11(10):2362) ran a randomised, placebo-controlled, crossover, double-blind trial. Thirty healthy adults (9 men, 21 women; mean age 48.3 +/- 11.9 years) with no major psychiatric illness received L-theanine 200 mg/day or placebo for four weeks each. Stress-related scores fell after L-theanine on the Self-rating Depression Scale (p = 0.019), the State-Trait Anxiety Inventory-trait (p = 0.006) and the Pittsburgh Sleep Quality Index (p = 0.013). The PSQI subscales for sleep latency, sleep disturbance and use of sleep medication improved versus placebo (all p < 0.05). Cognitive scores improved for verbal fluency (p = 0.001) and executive function (p = 0.031). A stratified analysis showed the verbal fluency gain was concentrated in participants below the median at baseline (p = 0.002).

Dassanayake et al. (Nutritional Neuroscience 2022;25(4):698-708) used a double-blind, placebo-controlled, counterbalanced four-way crossover design in 27 healthy young adults, comparing L-theanine 100 mg, 200 mg and 400 mg against placebo on cognitive event-related potentials in an auditory stimulus discrimination task, measured before and 50 minutes after dosing. The 400 mg dose significantly shortened the latency of the parietal P3b component (p < 0.05). An exploratory regression estimated a 4 ms reduction in P3b latency per 100 mg increment (p < 0.05).

Read together these trials give a consistent, dose-dependent picture: measurable effects on self-rated stress, on sleep quality measured by PSQI, and on attention-related neurophysiology, at 200 to 400 mg taken orally. L-theanine is in this formula for the calm-focus character it contributes.

Fucoxanthin is a xanthophyll carotenoid from brown seaweed (Undaria pinnatifida, Laminaria japonica). The human evidence consists of double-blind, randomised, placebo-controlled trials using the ORAL route.

The most cited is Abidov et al. (Diabetes, Obesity and Metabolism 2010;12(1):72-81): a 16-week double-blind, randomised, placebo-controlled study in 151 non-diabetic obese premenopausal women, stratified by liver fat content (non-alcoholic fatty liver disease, liver fat above 11%, n = 113; normal liver fat, below 6.5%, n = 38). The active arm received Xanthigen-600, a COMBINATION product - 300 mg pomegranate seed oil plus 300 mg brown seaweed extract standardised to 2.4 mg fucoxanthin - so the result belongs to the combination rather than to fucoxanthin alone. Body weight fell by 5.5 +/- 1.4 kg in the NAFLD group and 4.9 +/- 1.2 kg in the normal-liver-fat group (p < 0.05). Body fat fell by 3.5 +/- 1.9 kg (p < 0.001) and 3.6 +/- 0.7 kg (p < 0.05) respectively. Liver fat content, liver enzymes, serum triglycerides and C-reactive protein also decreased. Fucoxanthin above 2.4 mg and Xanthigen-400/1.6 mg significantly increased resting energy expenditure versus placebo.

An independent trial tested fucoxanthin on its own. Lopez-Ramos et al. (Journal of Medicinal Food 2023;26(7):521-527; ClinicalTrials.gov NCT03613740) randomised 28 patients with metabolic syndrome to 12 mg fucoxanthin or placebo once daily for 12 weeks, double-blind. After treatment: body weight 80.6 +/- 11.2 to 79.2 +/- 12.3 kg (p < 0.01); BMI 31.1 +/- 3.6 to 30.3 +/- 3.7 kg/m2 (p < 0.01); waist circumference 101.2 +/- 9.1 to 98.9 +/- 9.3 cm (p < 0.01); systolic blood pressure 126.1 +/- 10.3 to 120.8 +/- 9.7 mmHg (p < 0.01); diastolic 81.5 +/- 6.5 to 78.6 +/- 6.3 mmHg (p < 0.01); triglycerides 2.2 +/- 0.7 to 2.1 +/- 0.7 mmol/L (p < 0.01). First-phase insulin secretion (Stumvoll index) and total insulin secretion increased (both p < 0.05).

Route and dose studied: oral capsules, 1.6 to 12 mg/day.